v3.26.1
Liabilities Related to Future Royalties and Milestones, Net - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 06, 2024
USD ($)
Feb. 29, 2024
USD ($)
Dec. 31, 2022
USD ($)
payment
Nov. 30, 2021
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Nov. 08, 2024
USD ($)
Class of Warrant or Right [Line Items]                    
Interest expense on liabilities related to future royalties and milestones, net         $ 12,447 $ 10,681 $ 23,477 $ 20,819    
Cumulative catch-up adjustment         15,200 $ 17,500 15,171 $ 17,500    
Liability related to future royalties and milestones         284,300   284,300   $ 280,200  
Blackstone                    
Class of Warrant or Right [Line Items]                    
Upfront payment paid       $ 50,000            
Number of development payments | payment     2              
Liability related to future royalties and milestones     $ 35,000   $ 240,900   $ 240,900   236,700  
Remaining performance obligation, variable consideration amount                   $ 30,000
Effective percentage         15.80% 15.80% 15.80% 15.80%    
BioNTech                    
Class of Warrant or Right [Line Items]                    
Liability related to future royalties and milestones         $ 43,400   $ 43,400   $ 43,500  
Effective percentage         28.70% 28.70% 28.70% 28.70%    
BioNTech | Obe-cel Product                    
Class of Warrant or Right [Line Items]                    
Upfront payment paid $ 40,000                  
Remaining performance obligation, variable consideration amount $ 100,000                  
Initial recognition of liability   $ 38,300